NZ590668A - TNF-alpha ANTAGONIST MULTI-TARGET BINDING PROTEINS - Google Patents
TNF-alpha ANTAGONIST MULTI-TARGET BINDING PROTEINSInfo
- Publication number
- NZ590668A NZ590668A NZ590668A NZ59066809A NZ590668A NZ 590668 A NZ590668 A NZ 590668A NZ 590668 A NZ590668 A NZ 590668A NZ 59066809 A NZ59066809 A NZ 59066809A NZ 590668 A NZ590668 A NZ 590668A
- Authority
- NZ
- New Zealand
- Prior art keywords
- tnf
- binding proteins
- target binding
- fusion proteins
- alpha antagonist
- Prior art date
Links
- 108060008682 Tumor Necrosis Factor Proteins 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title abstract 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 title 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 title 1
- 102000023732 binding proteins Human genes 0.000 title 1
- 108091008324 binding proteins Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 abstract 5
- 108020001507 fusion proteins Proteins 0.000 abstract 5
- 239000000203 mixture Substances 0.000 abstract 2
- 108010028006 B-Cell Activating Factor Proteins 0.000 abstract 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 abstract 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 abstract 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 abstract 1
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 abstract 1
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 abstract 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 abstract 1
- 102100025947 Insulin-like growth factor II Human genes 0.000 abstract 1
- 102000003814 Interleukin-10 Human genes 0.000 abstract 1
- 108090000174 Interleukin-10 Proteins 0.000 abstract 1
- 102100033461 Interleukin-17A Human genes 0.000 abstract 1
- 102000004889 Interleukin-6 Human genes 0.000 abstract 1
- 108090001005 Interleukin-6 Proteins 0.000 abstract 1
- 102000000704 Interleukin-7 Human genes 0.000 abstract 1
- 108010002586 Interleukin-7 Proteins 0.000 abstract 1
- 102000014128 RANK Ligand Human genes 0.000 abstract 1
- 108010025832 RANK Ligand Proteins 0.000 abstract 1
- 102100040247 Tumor necrosis factor Human genes 0.000 abstract 1
- 102100024584 Tumor necrosis factor ligand superfamily member 12 Human genes 0.000 abstract 1
- 101710097155 Tumor necrosis factor ligand superfamily member 12 Proteins 0.000 abstract 1
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 abstract 1
- 230000001270 agonistic effect Effects 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- FOCAHLGSDWHSAH-UHFFFAOYSA-N difluoromethanethione Chemical compound FC(F)=S FOCAHLGSDWHSAH-UHFFFAOYSA-N 0.000 abstract 1
- 238000006471 dimerization reaction Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Physics & Mathematics (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13409708P | 2008-07-02 | 2008-07-02 | |
| US13409508P | 2008-07-02 | 2008-07-02 | |
| US13409608P | 2008-07-02 | 2008-07-02 | |
| US13410108P | 2008-07-02 | 2008-07-02 | |
| US13409808P | 2008-07-02 | 2008-07-02 | |
| US13410008P | 2008-07-02 | 2008-07-02 | |
| US13409908P | 2008-07-02 | 2008-07-02 | |
| US18009709P | 2009-05-20 | 2009-05-20 | |
| PCT/US2009/049603 WO2010003108A2 (en) | 2008-07-02 | 2009-07-02 | TNF-α ANTAGONIST MULTI-TARGET BINDING PROTEINS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ590668A true NZ590668A (en) | 2012-12-21 |
Family
ID=41051379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ590668A NZ590668A (en) | 2008-07-02 | 2009-07-02 | TNF-alpha ANTAGONIST MULTI-TARGET BINDING PROTEINS |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20110152173A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2310410A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2011526792A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20110044991A (cg-RX-API-DMAC7.html) |
| CN (1) | CN102171247A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009266863A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0914005A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2729749A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201170028A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL210264A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2011000041A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ590668A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010003108A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2537015T3 (es) | 2003-03-19 | 2015-06-01 | Biogen Ma Inc. | Proteína de unión del receptor de NOGO |
| PL1776136T3 (pl) | 2004-06-24 | 2013-03-29 | Biogen Ma Inc | Leczenie stanów związanych z demielinizacją |
| ES2434470T3 (es) | 2005-07-08 | 2013-12-16 | Biogen Idec Ma Inc. | Anticuerpos SP35 y usos de éstos |
| WO2008027986A2 (en) | 2006-09-01 | 2008-03-06 | Therapeutic Human Polyclonals, Inc. | Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals |
| AU2009266856A1 (en) * | 2008-07-02 | 2010-01-07 | Emergent Product Development Seattle, Llc | IL6 immunotherapeutics |
| DK2982695T3 (da) * | 2008-07-09 | 2019-05-13 | Biogen Ma Inc | Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf |
| NZ603623A (en) * | 2008-10-10 | 2014-05-30 | Emergent Product Dev Seattle | Tcr complex immunotherapeutics |
| EP2516467A2 (en) * | 2009-12-23 | 2012-10-31 | Emergent Product Development Seattle, LLC | Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof |
| KR101004362B1 (ko) * | 2010-03-19 | 2010-12-28 | 가톨릭대학교 산학협력단 | 자가 면역 질환 예방 및 치료용 ＴＮＦ－α와 ＴＷＥＡＫ 이중 길항제 |
| KR101004363B1 (ko) | 2010-03-19 | 2010-12-28 | 가톨릭대학교 산학협력단 | 자가 면역 질환 예방 및 치료용 ＴＮＦ－α와 ＩＬ－２１ 이중 길항제 |
| BR112013007501B1 (pt) * | 2010-09-30 | 2022-04-19 | Chengdu Kanghong Biotechnologies Co., Ltd. | Anticorpo humanizado anti-fator de necrose tumoral a, ou um fragmento de ligação ao antígeno do mesmo, uso e composição farmacêutica |
| CN107474133B (zh) * | 2011-02-08 | 2021-10-15 | 米迪缪尼有限公司 | 特异性结合金黄色葡萄球菌α毒素的抗体以及使用方法 |
| EP2784080B1 (en) * | 2011-10-31 | 2019-12-18 | Shimadzu Corporation | Peptide-hinge-free flexible antibody-like molecule |
| WO2013075027A2 (en) * | 2011-11-17 | 2013-05-23 | Emergent Product Development Seattle, Llc | Anti-sil6xr complex binding domains and methods of use |
| EP2791338B1 (en) | 2011-12-15 | 2019-02-20 | The Royal Institution for the Advancement of Learning / McGill University | Soluble igf receptor fc fusion proteins and uses thereof |
| US9284283B2 (en) | 2012-02-02 | 2016-03-15 | Ensemble Therapeutics Corporation | Macrocyclic compounds for modulating IL-17 |
| EP2834273B1 (en) | 2012-04-05 | 2018-08-22 | F.Hoffmann-La Roche Ag | Bispecific antibodies against human tweak and human il17 and uses thereof |
| MX366813B (es) | 2012-04-20 | 2019-07-25 | Aptevo Res & Development Llc | Polipeptidos de enlace cd3. |
| ES2749200T3 (es) | 2012-05-10 | 2020-03-19 | Bioatla Llc | Anticuerpos monoclonales multiespecíficos |
| EA030716B1 (ru) | 2012-05-14 | 2018-09-28 | Байоджен Ма Инк. | Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны |
| CN103060274B (zh) * | 2012-12-28 | 2013-12-11 | 首都医科大学 | Rankl-tnf样区鼠源性单克隆抗体及其制备方法与应用 |
| EP2938634A2 (en) * | 2012-12-28 | 2015-11-04 | AbbVie Inc. | Dual specific binding proteins having a receptor sequence |
| NL2011406C2 (en) | 2013-09-06 | 2015-03-10 | Bionovion Holding B V | Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides. |
| US9416197B2 (en) | 2013-11-01 | 2016-08-16 | Ibc Pharmaceuticals, Inc. | Bispecific antibodies that neutralize both TNF-α and IL-6: novel therapeutic agent for autoimmune disease |
| US10435467B2 (en) | 2015-01-08 | 2019-10-08 | Biogen Ma Inc. | LINGO-1 antagonists and uses for treatment of demyelinating disorders |
| NL2014108B1 (en) | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
| AU2016304764C1 (en) | 2015-08-07 | 2023-06-01 | Imaginab, Inc. | Antigen binding constructs to target molecules |
| BR112018005573A2 (pt) | 2015-09-21 | 2019-01-22 | Aptevo Research And Development Llc | ?polipeptídeos de ligação a cd3? |
| JP7085992B2 (ja) * | 2015-10-29 | 2022-06-17 | エフ．ホフマン－ラ ロシュ アーゲー | 共通軽鎖を有するトランスジェニックウサギ |
| EP3293293A1 (en) * | 2016-09-08 | 2018-03-14 | Italfarmaco SpA | Hc-cdr3-only libraries with reduced combinatorial redundancy and optimized loop length distribution |
| US11266745B2 (en) | 2017-02-08 | 2022-03-08 | Imaginab, Inc. | Extension sequences for diabodies |
| JP7234142B2 (ja) | 2017-06-02 | 2023-03-07 | ファイザー・インク | Ｆｌｔ３に特異的な抗体およびその使用 |
| JP6895165B2 (ja) * | 2017-06-06 | 2021-06-30 | 知和 松浦 | α１−アンチキモトリプシンを含むバイオマーカー |
| EP3655439A1 (en) | 2017-07-20 | 2020-05-27 | Aptevo Research and Development LLC | Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods |
| MX2020013606A (es) | 2018-06-14 | 2021-05-27 | Bioatla Inc | Constructos de anticuerpos multiespecificos. |
| BR112021001214A2 (pt) | 2018-07-24 | 2021-04-27 | Medimmune, Llc | anticorpo dirigido contra o fator de aglutinação a (clfa) de s. aureus |
| US11168133B2 (en) | 2018-10-09 | 2021-11-09 | Medimmune, Llc | Combinations of anti-Staphylococcus aureus antibodies |
| KR102404684B1 (ko) * | 2019-01-15 | 2022-06-07 | 서울대학교산학협력단 | 인슐린 유사 성장인자 2 억제제를 포함하는 만성 폐질환의 예방 또는 치료용 조성물 |
| AU2020329217A1 (en) | 2019-08-12 | 2022-07-28 | Aptevo Research And Development Llc | 4-1BB and OX40 binding proteins and related compositions and methods, antibodies against 4-1BB, antibodies against OX40 |
| KR20220127843A (ko) | 2020-01-13 | 2022-09-20 | 압테보 리서치 앤드 디벨롭먼트 엘엘씨 | 단백질 치료제용 제형 |
| WO2022103660A1 (en) * | 2020-11-11 | 2022-05-19 | Hq Han | Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof |
| CN112451670B (zh) * | 2020-11-25 | 2024-01-02 | 沣潮医药科技（上海）有限公司 | 异位内膜治疗的组合物和预后检测试剂盒 |
| AU2021390501A1 (en) | 2020-12-01 | 2023-06-29 | Aptevo Research And Development Llc | Heterodimeric psma and cd3-binding bispecific antibodies |
| CN115073607A (zh) * | 2021-03-12 | 2022-09-20 | 上海康岱生物医药技术股份有限公司 | Tnfr2与baff受体的融合蛋白 |
| AU2022276523A1 (en) | 2021-05-21 | 2024-01-18 | Aptevo Research And Development Llc | Dosing regimens for protein therapeutics |
| CN117136196A (zh) * | 2022-03-03 | 2023-11-28 | 上海赛金生物医药有限公司 | 一种重组融合蛋白的制剂 |
| WO2023178306A2 (en) * | 2022-03-18 | 2023-09-21 | Fab Biopharma, Inc. | Compositions and methods for treatment of sjögren's syndrome and/or systemic lupus erythematosus |
| EP4646442A2 (en) | 2023-01-06 | 2025-11-12 | Aptevo Research and Development LLC | Bispecific pd-l1 and cd40 binding molecules and uses thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3883899T3 (de) * | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US5714585A (en) * | 1987-10-26 | 1998-02-03 | Sterling Winthrop, Inc. | Antibodies that are immunoreactive with interleukin-7 |
| ATE173630T1 (de) * | 1992-12-29 | 1998-12-15 | Genentech Inc | Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren |
| US20050147609A1 (en) * | 1998-05-15 | 2005-07-07 | Genentech, Inc. | Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis |
| HUP0105044A3 (en) * | 1999-01-15 | 2004-07-28 | Biogen Inc Cambridge | Antagonists of tweak and of tweak receptor and their use to treat immunological disorders |
| US7220840B2 (en) * | 2000-06-16 | 2007-05-22 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator protein |
| EP1401870A4 (en) * | 2001-05-24 | 2006-04-19 | Human Genome Sciences | ANTIBODIES AGAINST TUMOR NECROSIS FACTOR DELTA (APRIL) |
| US20060073141A1 (en) * | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| DE10148217C1 (de) * | 2001-09-28 | 2003-04-24 | Bosch Gmbh Robert | Verfahren, Computerprogramm und Steuer- und/oder Regelgerät zum Betreiben einer Brennkraftmaschine, sowie Brennkraftmaschine |
| WO2003068920A2 (en) * | 2002-02-13 | 2003-08-21 | Ludwig Institute For Cancer Research | Humanized gm-csf antibodies |
| CN1692127A (zh) * | 2002-07-25 | 2005-11-02 | 健泰科生物技术公司 | Taci抗体及其用途 |
| TW200607523A (en) * | 2004-06-01 | 2006-03-01 | Domantis Ltd | Drug compositions, fusions and conjugates |
| KR20080022539A (ko) * | 2004-10-12 | 2008-03-11 | 앰프로틴 코포레이션 | 키메라 단백질 |
| WO2006063150A2 (en) * | 2004-12-08 | 2006-06-15 | Immunomedics, Inc. | Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer |
| US7939490B2 (en) * | 2004-12-13 | 2011-05-10 | University Of Maryland, Baltimore | TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death |
| AU2006230099B2 (en) * | 2005-03-25 | 2012-04-19 | Gitr, Inc. | GITR binding molecules and uses therefor |
| ME02059B (me) * | 2005-05-18 | 2015-05-20 | Morphosys Ag | Protutijela protiv gm-csf i njihova upotreba |
| WO2006130429A2 (en) * | 2005-05-27 | 2006-12-07 | Biogen Idec Ma Inc. | Treatment of cancer |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| NZ597168A (en) * | 2005-08-19 | 2013-07-26 | Abbott Lab | Dual variable domain immunoglobin and uses thereof |
| WO2007087673A1 (en) * | 2006-02-01 | 2007-08-09 | Arana Therapeutics Limited | Domain antibody construct |
| MX2008015524A (es) * | 2006-06-12 | 2009-01-13 | Trubion Pharmaceuticals Inc | Proteinas de union multivalentes monocatenarias con funcion efectora. |
| JP2011526794A (ja) * | 2008-07-02 | 2011-10-20 | エマージェント プロダクト デベロップメント シアトル， エルエルシー | ＴＧＦ−βアンタゴニスト多重標的結合性分子 |
| AU2009266856A1 (en) * | 2008-07-02 | 2010-01-07 | Emergent Product Development Seattle, Llc | IL6 immunotherapeutics |
| WO2010014629A1 (en) * | 2008-07-28 | 2010-02-04 | Trubion Pharmaceuticals, Inc. | Multi-specific binding proteins targeting b cell disorders |
| CA2739460C (en) * | 2008-10-02 | 2019-05-21 | Emergent Product Development Seattle, Llc | Cd86 antagonist multi-target binding proteins |
| NZ603623A (en) * | 2008-10-10 | 2014-05-30 | Emergent Product Dev Seattle | Tcr complex immunotherapeutics |
-
2009
- 2009-07-02 EP EP09774557A patent/EP2310410A2/en not_active Withdrawn
- 2009-07-02 CN CN2009801338489A patent/CN102171247A/zh active Pending
- 2009-07-02 CA CA2729749A patent/CA2729749A1/en not_active Abandoned
- 2009-07-02 JP JP2011516886A patent/JP2011526792A/ja active Pending
- 2009-07-02 NZ NZ590668A patent/NZ590668A/xx not_active IP Right Cessation
- 2009-07-02 EA EA201170028A patent/EA201170028A1/ru unknown
- 2009-07-02 US US13/001,087 patent/US20110152173A1/en not_active Abandoned
- 2009-07-02 WO PCT/US2009/049603 patent/WO2010003108A2/en not_active Ceased
- 2009-07-02 KR KR1020117002700A patent/KR20110044991A/ko not_active Withdrawn
- 2009-07-02 BR BRPI0914005A patent/BRPI0914005A2/pt not_active IP Right Cessation
- 2009-07-02 AU AU2009266863A patent/AU2009266863A1/en not_active Abandoned
- 2009-07-02 MX MX2011000041A patent/MX2011000041A/es not_active Application Discontinuation
-
2010
- 2010-12-26 IL IL210264A patent/IL210264A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2729749A1 (en) | 2010-01-07 |
| US20110152173A1 (en) | 2011-06-23 |
| BRPI0914005A2 (pt) | 2015-11-17 |
| EA201170028A1 (ru) | 2011-12-30 |
| WO2010003108A2 (en) | 2010-01-07 |
| WO2010003108A3 (en) | 2010-02-25 |
| EP2310410A2 (en) | 2011-04-20 |
| AU2009266863A1 (en) | 2010-01-07 |
| IL210264A0 (en) | 2011-03-31 |
| MX2011000041A (es) | 2011-05-23 |
| CN102171247A (zh) | 2011-08-31 |
| KR20110044991A (ko) | 2011-05-03 |
| JP2011526792A (ja) | 2011-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ590668A (en) | TNF-alpha ANTAGONIST MULTI-TARGET BINDING PROTEINS | |
| NZ590667A (en) | Tgf-b antagonist multi-target binding proteins | |
| NZ592420A (en) | Cd86 antagonist multi-target binding proteins | |
| PH12015500806B1 (en) | Binding molecules to the human ox40 receptor | |
| SG163525A1 (en) | Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of muscle relaxation | |
| MX2025010937A (es) | Constructos de anticuerpo biespecificos que se ligan a celulas t | |
| NZ756763A (en) | Engineered transferrin receptor binding polypeptides | |
| PH12018501025A1 (en) | Improved tnf binders | |
| MX2019012953A (es) | Anticuerpo biespecifico contra ox40 y ctla-4. | |
| WO2014074532A3 (en) | Compositions and methods for modulating cell signaling | |
| EA201400568A1 (ru) | Альбуминсвязывающие антитела и их связывающие фрагменты | |
| MX2011011754A (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b. | |
| EA201170030A1 (ru) | Il-6-опосредованная иммунотерапия | |
| MY162737A (en) | 4-1bb binding molecules | |
| EA201001223A1 (ru) | Стабилизированные белковые композиции | |
| MX2011013172A (es) | Metodos para aumentar adipocitos termogenicos. | |
| EP3670536A3 (en) | Recombinant tnf ligand family member polypeptides with antibody binding domain and uses thereof | |
| MX2021000306A (es) | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno y fc modificados genéticamente dirigidos a ctla-4. | |
| WO2010142551A8 (en) | Amino acid sequences directed against receptors to cytokines belonging to the il-17 family | |
| WO2007146401A3 (en) | Denatured collagen peptides and uses thereof | |
| MX2021000307A (es) | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc dirigidos a cd38 diseñados por ingeniería genética. | |
| NZ629309A (en) | Tumour necrosis factor receptor fusion proteins and methods of using the same | |
| WO2013043070A3 (en) | Anti-tumor necrosis factor-alpha agents and uses thereof | |
| PH12021551422A1 (en) | Anti-il-36 antibodies and methods of use thereof | |
| MX2021000281A (es) | Composiciones y métodos relacionados con construcciones de dominio de unión a antígeno y fc modificadas genéticamente dirigidas a pd-l1. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 02 JUL 2016 BY COMPUTER PACKAGES INC Effective date: 20130726 |
|
| LAPS | Patent lapsed |